December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
2 citations
,
April 2018 in “Journal of Investigative Dermatology” Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.
2 citations
,
April 2017 in “Molecular Medicine Reports” Blocking autophagy increases survival of inner ear hair cells exposed to gentamicin.
January 2020 in “Springer eBooks”
9 citations
,
January 2013 in “Journal of Cutaneous and Aesthetic Surgery” Transplanting body hair helped repigment and treat a man's vitiligo.
102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
25 citations
,
March 2012 in “Journal of oncology pharmacy practice” An 81-year-old man's white hair began to regain its original color while he was treated with lenalidomide, suggesting that graying hair might be reversible.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
August 2023 in “Journal of The American Academy of Dermatology” Valproic acid, a common antiepileptic medication, can cause reversible hair loss in patients.
24 citations
,
October 2022 in “Cell Regeneration” A new mouse model effectively mimics vitiligo for research and drug testing.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
July 2024 in “Journal of Investigative Dermatology” Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.
16 citations
,
April 2000 in “Journal of Investigative Dermatology” The AVET system effectively delivers genes to human keratinocytes and may help treat skin diseases.
7 citations
,
December 2013 in “The Journal of Dermatology” A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
11 citations
,
August 1988 in “PubMed” Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
1 citations
,
May 2019 in “Journal of pediatric endocrinology & metabolism/Journal of pediatric endocrinology and metabolism” Intravenous calcium therapy is a safe and effective treatment for a rare type of rickets.
4 citations
,
March 2023 in “Current Oncology” Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.
Multiphoton microscopy helps understand and improve vitiligo treatments by visualizing skin cell changes.
52 citations
,
February 2009 in “Journal of the American Academy of Dermatology” A 93-year-old woman developed a rare scalp condition after therapy, which improved with steroids, not antibiotics.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
10 citations
,
June 2011 in “Archives of Dermatology” Finasteride caused blisters on hands and feet.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
3 citations
,
July 2025 in “British Journal of Dermatology” Cinainu is effective and safe for treating children's alopecia areata.
3 citations
,
January 2015 in “Journal of clinical and diagnostic research” Treating a boy's scalp infection was challenging because two different colors of the same fungus appeared.
June 2021 in “Asian Journal of Medical Sciences” Vitamin B12 deficiency can cause reversible skin darkening.
November 2025 in “Indian Journal of Nephrology” Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.